VISITAS RECIENTES

AUTISMO TEA PDF

AUTISMO TEA PDF
TRASTORNO ESPECTRO AUTISMO y URGENCIAS PDF

We Support The Free Share of the Medical Information

Enlaces PDF por Temas

Nota Importante

Aunque pueda contener afirmaciones, datos o apuntes procedentes de instituciones o profesionales sanitarios, la información contenida en el blog EMS Solutions International está editada y elaborada por profesionales de la salud. Recomendamos al lector que cualquier duda relacionada con la salud sea consultada con un profesional del ámbito sanitario. by Dr. Ramon REYES, MD

Niveles de Alerta Antiterrorista en España. Nivel Actual 4 de 5.

Niveles de Alerta Antiterrorista en España. Nivel Actual 4 de 5.
Fuente Ministerio de Interior de España
Showing posts with label BURN. Show all posts
Showing posts with label BURN. Show all posts

Thursday, February 8, 2024

NEW BURN TREATMENT ReCell ® Spray-On Skin ™


Tea-scald toddler Zed Merrick given spray-on skin

A mother of a Lincolnshire toddler who was badly burnt says the result of a spray-on skin treatment was "amazing".
Two-year-old Zed Merrick, from Ulceby, spilled a hot cup of tea over himself last October, which left him severely scalded.
Doctors carried out a procedure where Zed's skin cells were sprayed on to the injury on his chest from an aerosol.
Zed's mother Nicky Merrick said the treatment has now left her son almost scar free.
She said at the time he was "obviously in a lot of pain and screaming".
'Peeling away'
"My mum was making a cup of tea and Zed ran in so quickly and pulled it all over himself before we could see him move," Ms Merrick said.
"My mum ripped his t-shirt off him, she wanted to get the hot shirt off his chest, I threw a jug of water over his chest and our neighbour got us both into the shower to get the cold water running on him.


"Straight away the skin was peeling away, similar to when you get sunburnt and your skin starts to peel, it was very red and very sore."
Ms Merrick said her neighbour, who was a nurse, put cold towels on Zed's chest and replaced them as they got hot until the paramedic arrived.
"We didn't realise at the time how spectacular the treatment is and how amazing the results can be.
"They take a sample of skin and turn into a spray. They sprayed that on to his chest and it helped the cells renew, grow and adapt."
Ms Merrick said she had no fear of the cells being rejected because they had been taken from Zed.
"His skin was very pink at first, but over the weeks it got paler and paler now you can't even see it that much now," she said.
'Healthy skin cells'
The ReCell Spray-On Skin treatment, developed by Avita Medical, was carried out in October 2011. It has taken four months for Zed's chest to look almost scar free.
Claire Darby, the company's clinical manager, said: "Essentially, ReCell is able to harness the body's natural ability to heal itself.
"It allows the surgeon to harvest all the healthy skin cells required to form normal healthy looking skin again as a one-step procedure.
"If the patient is treated early this will reduce the risk of scarring and chance of infection."
Ms Merrick added that the alternative treatment would have been skin graft.
"That could have meant several weeks in hospital, multiple operations and very painful bandage changes," she said. 


Link BBC News

Sunday, December 25, 2022

European Burn Guidelines

European Burn Guidelines Version 4  2017 
e-book 




European Burns Association
European Practice Guidelines for Burn Care Minimum level of Burn Care Provision in Europe

2011 - First Edition - The Hague/The Netherlands 
2013 - Second Edition - Vienna/Austria 
2015 - Third Edition – Hannover/Germany 

Link to downlad PDF 


Saturday, September 24, 2022

Burn patient management guidelines 4th Edition. 2019 pdf

Burn patient management guidelines 4th Edition. 2019 pdf

DESCARGAR DOWNLOAD 



Dr Ramon REYES, MD,
Por favor compartir nuestras REDES SOCIALES @DrRamonReyesMD, así podremos llegar a mas personas y estos se beneficiarán de la disponibilidad de estos documentos, pdf, e-book, gratuitos y legales..


Wednesday, December 15, 2021

Resources for National Burn Awareness Day TOOLKIT

 


Download E-Book "PDF" 2.23 MB

27 pages 



Downloadable Resources

Resources for National Burn Awareness Day 2021 can be downloaded below. Click on each link to download them directly to your computer.

LogoNational Burn
Awareness Day logo
Download
ToolkitEverything you need to
know about
raising awareness
Download
A4 Poster – Child
(Hot Drinks)

A poster highlighting
hot drinks as
the main cause of burns

Download
A4 Poster – AdultA poster for adult
burn awareness
Download
A4 Poster – Child
A poster for child
burn awareness
Download
Hospital Event
Planner
A guide for Hospitals
when planning
National Burn
Awareness Day
events
Download
Parent Hot Drink 
Policy
Case study for parents
and children’s
centres
Download
Email signatureInsert on the bottom of
all e-mails to raise
awareness
Download
Facebook coverInsert as your
Facebook cover
image
Download
Facebook postPost for
Facebook
Download
Instagram postPost for
Instagram
Download
Twitter headerInsert as your
Twitter header
Download
Twitter postPost for
Twitter
Download
LinkedIn headerInsert as your
LinkedIn header
Download
LinkedIn postPost for LinkedInDownload
Facebook Post (Hot Drinks)Post for FacebookDownload
Twitter Post (Hot Drinks)Post for TwitterDownload
Instagram (Hot Drinks)Post for InstagramDownload

Please email us for A3 print ready versions of the posters. Welsh versions of the posters are also available.

  • Help to raise awareness of the shocking number of people burned each and every day – the vast majority of which are preventable
  • Promote good first aid

The importance and reach of National Burn Awareness Day has grown year-on-year.  Hospitals, Burns Services, Community Health, Fire & Rescue Services around the country are among the many organisations that hold awareness raising events.

Monday, September 28, 2020

Trauma/Burn Clinical Guidelines. A Quick Guide for the Management of Trauma/Burn Disasters for Emergency Department Personnel Rev. August 2013


Trauma/Burn Clinical Guidelines. A Quick Guide for the Management of Trauma/Burn Disasters for Emergency Department Personnel Rev. August 2013


Post by 




  1. imon J Mercer, consultant anaesthetist1,  
  2. Elizabeth V Kingston, specialty trainee in anaesthesia2,  
  3. Clinton P L Jones, consultant anaesthetist1
    Author affiliations
  1. Correspondence to S Mercer simonjmercer@hotmail.com

What you need to know

  • A trauma team assembles rapidly in response to a major trauma alert and has a dedicated leader, usually an emergency medicine consultant, supported by a multidisciplinary team.
  • Initial rapid assessment follows the mnemonic ABCD with control of catastrophic bleeding, assessment of airway, breathing, circulation, and disability.
  • Initial investigations to guide early management include portable radiography for chest and pelvis, point of care testing for venous blood gas analysis, and assessment of coagulation status.
  • The team leader co-ordinates care, following the principles of damage control resuscitation to control bleeding and restore tissue perfusion.
Trauma is the leading cause of death for people under 40 in the UK, and a major cause of debilitating long-term injuries.1 Major trauma usually refers to a seriously injured patient or a patient with multiple injuries requiring a coordinated multidisciplinary approach to their care. Twenty percent of patients in the UK survive severe trauma. 2An audit of the major trauma services in England identified deficiencies in care contributing to high in-hospital mortality in trauma patients.2 Typically, such patients are managed in the emergency department after a trauma call is put out to assemble a trauma team. The trauma team must rapidly assess seriously injured patients and start treatment in a timely manner.
Here we aim to help clinicians familiarise themselves with the essentials of managing patients with major trauma as part of a team in an emergency department, drawing from our experience, and from 2017 guidelines from the UK’s National Institute for Health and Care Excellence (NICE) for head injury and major trauma. The practice and team constitution may differ based on resources and organisation of health services in different countries, however we expect the basic principles of organising and responding as a trauma team will be relevant.

Who is involved in a trauma team?

Trauma teams are assembled rapidly by …


https://www.bmj.com/content/bmj/suppl/2018/06/14/bmj.k2272.DC1/trauma_call_v34.pdf 

https://sandpit.bmj.com/site_images/2018/trauma_call_v35_web.png

https://emssolutionsint.blogspot.com/2013/10/traumaburn-clinical-guidelines-quick.html

Trauma Call Timeline
#Trauma #Timeline #Emergency #Checklist #Assessment #Mnemonic #BMJ




TELEFUNKEN AED DESFIBRILADOR FULL AUTOMATICO "0" RIESGOS 
DISPONIBLE EN AMERICA (REPUBLICA DOMINICANA)
Contactos:

eeiispain@gmail.com

Facebook: @drramonreyesmd     https://www.facebook.com/DrRamonReyesMD/
LinkeIn https://es.linkedin.com/in/drramonreyes
Twitter: @DrtoleteMD
Instagram: https://www.instagram.com/drtolete/





subitusint@gmail.com
https://emssolutionsint.blogspot.com/2019/06/subitus-international.html








  GEOLOCALIZACION Desfibriladores 
Republica Dominicana 

TELEGRAM Sociedad Iberoamericana de Emergencias https://t.me/joinchat/GRsTvEHYjNLP8yc6gPXQ9Q      

Monday, October 15, 2018

Confirmed by PRAC that hydroxyethyl-starch solutions (HES) should no longer be used in patients with sepsis or burn injuries or in critically ill patients. 11/10/2013

hydroxyethyl-starch solutions (HES) should no longer be used in patients with sepsis or burn injuries or in critically ill patients. 11/10/2013

PRAC confirms that hydroxyethyl-starch solutions (HES) should no longer be used in patients with sepsis or burn injuries or in critically ill patients

HES will be available in restricted patient populations
The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has completed its review of HES solutions following an assessment of new information and commitments from companies for additional studies and risk minimisation activities. The Committee confirmed that HES solutions must no longer be used to treat patients with sepsis (bacterial infection in the blood) or burn injuries or critically ill patients, because of an increased risk of kidney injury and mortality. HES solutions may, however, continue to be used in patients to treat hypovolaemia (low blood volume) caused by acute blood loss, provided that appropriate measures are taken to reduce potential risks and that additional studies are carried out.
The review of HES solutions was initially triggered by the German medicines agency, the Federal Institute for Drugs and Medical Devices (BfArM), following studies showing an increased risk of mortality in patients with sepsis and an increased risk of kidney injury requiring dialysis in critically ill patients following treatment with HES solutions.
The PRAC had initially concluded on 13 June 2013 that HES solutions should be suspended in all patient populations. Since then, the PRAC has analysed and considered new evidence that was not available at the time of the initial recommendation, including new studies. The Committee has also looked at new proposals for additional risk minimisation measures, including restrictions on use and a commitment from the companies to conduct additional studies.
The PRAC, on the basis of all data available to date, considered whether a group of patients could be identified for whom HES treatment remains beneficial. The Committee concluded that there was clear evidence for an increased risk of kidney injury and mortality in critically ill and septic patients, and that therefore HES should no longer be used in these patients. However the PRAC agreed that HES could continue to be used in patients with hypovolaemia caused by acute blood loss where treatment with alternative infusions solutions known as ‘crystalloids’ alone are not considered to be sufficient. The PRAC acknowledged the need for measures to minimise potential risks in these patients and recommended that HES solutions should not be used for more than 24 hours and that patients’ kidney function should be monitored for at least 90 days. In addition, the PRAC requested that further studies be carried out on the use of these medicines in elective surgery and trauma patients.
The PRAC recommendation will now be sent to the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), for consideration at its meeting on 21-23 October 2013.

New review of hydroxyethyl-starch-containing solutions for infusion started. 12/07/2013
The European Medicines Agency (EMA) has started a new review of hydroxyethyl-starch (HES)-containing solutions for infusion, following the suspension of the use of these medicines in the United Kingdom (UK) on 27 June 2013.
The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) had recommended in June 2013 that these medicines be suspended in the European Union (EU), following an assessment of available data which concluded that their benefits do not outweigh the risks of kidney injury and mortality. However, the process to implement the PRAC’s recommendation across the EU has not yet begun since a number of marketing-authorisation holders have exercised their legal right to request a re-examination of the recommendation.
In the meantime, some Member States have taken action to suspend or limit the marketing or use of these medicines in their territories. In accordance with EU legislation, this type of action currently requires that a review procedure be carried out. Consequently, the UK has requested the PRAC to start this review procedure, which will run in parallel with the re-examination of the PRAC’s June 2013 recommendation.
The Agency invites all stakeholders (e.g. healthcare professionals, patients’ organisations, the general public) to submit data relevant to this procedure. Full details are available under the 'data submission' tab.
HES-containing solutions are volume expanders used to replace lost blood volume in hypovolaemia (low blood volume caused by dehydration or blood loss) and hypovolaemic shock (a steep fall in blood pressure caused by drop in blood volume). They are used in critically ill patients including patients with sepsis (bacterial infection of the blood), or burn or trauma injuries, or patients who are undergoing surgery. HES-containing solutions are given by infusion (drip) into a vein.
Infusion solutions containing HES belong to the class of colloids. There are two main types of volume expanders: crystalloids and colloids. Colloids contain large molecules such as starch, whereas crystalloids such as saline solutions contain smaller molecules. In the EU, HES-containing solutions for infusion have been approved via national procedures.
This review of HES solutions for infusion has been initiated at the request of the UK medicines agency, the Medicines and Healthcare Products Regulatory Agency (MHRA), under Article 107i of Directive 2001/83/EC, also known as the urgent Union procedure.
The review is being carried out by the Pharmacovigilance Risk Assessment Committee (PRAC), the committee responsible for the evaluation of safety issues for human medicines, which will make a set of recommendations. As these medicines are all authorised nationally, the PRAC recommendation will be forwarded to the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), which will adopt a final position. The CMDh is a regulatory body that represents the EU Member States, responsible for ensuring harmonised safety standards for medicines authorised via national procedures across the EU.
In June 2013, the PRAC adopted recommendations on HES solutions under Article 31 of Directive 2001/83/EC. A number of marketing-authorisation holders have requested a re-examination of these recommendations.
12/07/2013